Last reviewed · How we verify
Autologous blood transfusion
Autologous blood transfusion returns a patient's own previously collected blood to restore circulating volume and oxygen-carrying capacity.
Autologous blood transfusion returns a patient's own previously collected blood to restore circulating volume and oxygen-carrying capacity. Used for Blood loss management in surgical patients, Reduction of allogeneic transfusion requirements.
At a glance
| Generic name | Autologous blood transfusion |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Vaudois |
| Modality | Biologic |
| Therapeutic area | Hematology/Transfusion Medicine |
| Phase | Phase 3 |
Mechanism of action
This procedure involves collecting and storing a patient's own blood prior to surgery or treatment, then reinfusing it to replace blood loss and maintain hemoglobin levels. It eliminates the risk of transfusion-transmitted infections and immune reactions associated with allogeneic (donor) blood products. The approach is used to reduce dependence on banked blood supplies and improve patient safety.
Approved indications
- Blood loss management in surgical patients
- Reduction of allogeneic transfusion requirements
Common side effects
- Infection (if contamination occurs during collection/storage)
- Hemolysis
- Volume overload
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease (PHASE3)
- Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers. (NA)
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia (PHASE1)
- NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) (PHASE1)
- Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion (PHASE1)
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous blood transfusion CI brief — competitive landscape report
- Autologous blood transfusion updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Vaudois portfolio CI